Thyroid Eye Disease in Singapore Shows a Distinct East Asian Clinical Pattern

A 10-year retrospective series from Singapore captures thyroid eye disease as it presents in a multi-ethnic Southeast Asian population: often active, often visible on examination, and frequently complicated by ocular surface disease. Investigators reviewed the case records of all patients seen at a multidisciplinary Thyroid Eye Clinic between November 2002 and October 2012, yielding 174 patients with a broad spread of age, ethnicity, and severity. The cohort was predominantly Chinese, with smaller Malay and Indian groups, reflecting the local population mix and allowing a rare look at how TED behaves outside the more familiar Caucasian datasets.

The age distribution was wide, stretching from infancy to older adulthood, with a mean age of 40.2 years. Women outnumbered men, but men still accounted for more than a third of the cohort, a reminder that TED is not a female-only disease even when it is more common in women. Disease severity skewed toward the mild end overall, yet the clinic still saw a substantial burden of moderate and severe orbitopathy. The most common ophthalmic signs were eyelid retraction, proptosis, and lid lag. Each of those findings maps to a different part of the same pathobiology: inflammatory expansion of orbital tissues, eyelid tethering, and anterior displacement of the globe.

Corneal involvement stood out. The single most clinically consequential observation was the frequency of corneal erosions, present in 29.3% of patients. Acquired epiblepharon appeared in 11.5% of the cohort, a figure that matters because the abnormal lash-globe interaction can drive repeated epithelial injury. In East Asian patients, this anatomic tendency appears to shape the surface manifestations of TED in a way that is less prominent in many Western series. A corneal problem can become the first sign that the orbit is affecting the front of the eye.

Ocular Surface Disease and Epiblepharon Drive a Large Share of Morbidity

The data suggest that clinicians caring for Asian patients with TED should look beyond the orbit and interrogate the ocular surface carefully. Epiblepharon is not merely an anatomic curiosity here; in this series it tracked with corneal erosion, and the combination can produce persistent irritation, punctate damage, and symptomatic exposure. In practical terms, a patient may appear to have only eyelid fullness or modest proptosis while already carrying clinically important corneal injury. This helps explain why careful slit-lamp assessment matters even when the external signs seem limited.

The mean exophthalmometry reading was 18.8 mm, with a range from 10.0 to 28.0 mm. Compared with the Caucasian experience cited by the investigators, the average degree of proptosis and the frequency of upper eyelid retraction and edema were lower in this Singapore cohort. The pattern is important because it suggests that TED does not look identical across ethnic groups, and a clinician trained on one population may underestimate disease when viewing another. Malay patients in the series had the highest exophthalmometry reading among the ethnic subgroups examined.

Eight patients, or 4.6%, had dysthyroid optic neuropathy. Even in a cohort where most disease was mild, optic nerve compression still emerged as a real and urgent complication. The number is small, but the bedside implication is immediate: reduced acuity, color desaturation, afferent pupillary defect, or progressive visual field compromise in TED should trigger rapid escalation rather than watchful waiting. Orbital crowding can remain silent until it is not.

Treatment Pattern Reflected Both Thyroid Control and Orbital Inflammation

Management in the cohort split between thyroid-directed therapy and orbit-directed intervention. Thyroid dysfunction was handled with anti-thyroid medication alone in 40.2% of patients, with smaller proportions receiving β blockers, thyroxine replacement, radioactive iodine, or a block-replace regimen. These numbers show the diversity of endocrine management pathways that accompany TED, and they also reinforce how often eye disease exists alongside fluctuating thyroid physiology rather than in isolation.

For active orbitopathy, intravenous corticosteroids were used in 12.1% of patients. That choice fits the inflammatory biology of TED, where immune-mediated orbital tissue expansion and edema can respond to high-dose steroid suppression. Surgical care was also substantial. Thyroidectomy was performed in 10.3% of patients, eyelid surgery in 8.6%, orbital decompression in 7.5%, epiblepharon correction in 2.3%, and strabismus surgery in 0.6%. The surgical mix tells its own story: some patients needed thyroid control, some needed surface protection, and others required decompression or alignment procedures to restore function and comfort.

The need for orbital decompression in a minority of patients sits alongside the larger burden of lid and corneal disease. A patient-centered reading of the series is hard to ignore. Many eyes needed no major surgery, but a notable fraction required procedures aimed at the orbit, lids, or cornea because the disease was affecting vision or daily comfort in ways that standard thyroid treatment could not fix on its own.

Why This Singapore Cohort Matters for Day-to-Day Ophthalmic Care

This series offers a useful corrective to the assumption that TED behaves the same everywhere. In Singapore, corneal erosion linked to acquired epiblepharon emerged as a common and clinically relevant feature, while proptosis and upper lid retraction were less pronounced on average than in Caucasian cohorts. Those differences matter because diagnosis, monitoring, and referral thresholds all depend on what clinicians expect to see. In an East Asian patient with irritation, tearing, and modest external change, the cornea may already be suffering.

The study also shows why multidisciplinary care is central to TED. Endocrinology, ophthalmology, medical management, and surgery all appeared in the same pathway, often for the same patient. A clinic built around that collaboration can identify optic neuropathy, manage thyroid disease, treat active inflammation, and address eyelid or surface complications before they become irreversible.

The series is retrospective and reflects a single tertiary center, so it cannot answer every question about incidence or natural history across Southeast Asia. It also does not provide a population denominator, which means these are clinic-based frequencies rather than community prevalence estimates. Even so, the message is concrete: in East Asian patients with TED, corneal erosion from acquired epiblepharon deserves front-line attention, and the pattern of external signs may be subtler than the classic Western description.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by BMJ.